| Symbol | XAIR |
|---|---|
| Name | BEYOND AIR, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Medical/Dental Instruments |
| Address | 900 STEWART AVENUE,SUITE 301, GARDEN CITY, New York, 11530, United States |
| Telephone | +1 516 - 665-8200 |
| Fax | — |
| — | |
| Website | https://www.beyondair.net |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001641631 |
| Description | Beyond Air Inc is a clinical-stage medical device and biopharmaceutical company which develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections. Additional info from NASDAQ: |
New Form SCHEDULE 13G/A - Beyond Air, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001172661-26-003442 <b>Size:</b> 15 KB
Read moreBeyond Air® Reports Financial Results for the Quarter Ended June 30, 2026 and Provides Corporate Update
Read moreBeyond Air® Reports Financial Results for the Quarter Ended June 30, 2026 and Provides Corporate Update
Read moreNASDAQ traded attribute type Financial_Status was changed. Previous value: Deficient. New value: Normal.
Read moreNASDAQ symbol attribute type Financial_Status was changed. Previous value: Deficient. New value: Normal.
Read moreBeyond Air Schedules Conference Call to Discuss Financial Results for the Quarter Ended June 30, 2026
Read moreBeyond Air Schedules Conference Call to Discuss Financial Results for the Quarter Ended June 30, 2026
Read moreBeyond Air® Announces Up to $30.1 Million Private Placement Offering Priced At-the-Market Under Nasdaq Rules
Read moreBeyond Air® Announces Up to $30.1 Million Private Placement Offering Priced At-the-Market Under Nasdaq Rules
Read moreNew Form SCHEDULE 13G/A - Beyond Air, Inc. <b>Filed:</b> 2026-07-16 <b>AccNo:</b> 0002144385-26-000002 <b>Size:</b> 5 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT05351502 | A Study to Assess the Safety and Efficacy of Nitric Oxide Injection Into Unrese… | Phase1 | Cancer | Recruiting | 2022-08-14 | 2025-06-30 | ClinicalTrials.gov |
| NCT04685720 | A Pilot Study to Assess the Effect of Intermittent iNO on the Treatment of NTM … | Na | Non-Tuberculous Mycobacterial Pneumonia | Completed | 2020-12-07 | 2022-10-10 | ClinicalTrials.gov |
| NCT04606407 | Inhaled NO for the Treatment of Viral Pneumonia in Adults | Na | Viral Pneumonia | Completed | 2020-11-25 | 2022-08-07 | ClinicalTrials.gov |
| NCT04456088 | Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (CANADA Trial) | Phase2 | COVID-19 | Withdrawn | 2020-07-15 | 2020-12-15 | ClinicalTrials.gov |
| NCT04397692 | Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (US Trial) | Na | Corona Virus Infection | Terminated | 2020-06-13 | 2020-09-30 | ClinicalTrials.gov |
| NCT04060979 | Evaluation of Two Doses of Nitric Oxide (NO) Given Intermittently Via Inhalatio… | Phase2 | Bronchiolitis Acute | Completed | 2019-11-06 | 2020-04-02 | ClinicalTrials.gov |
| NCT03208764 | Inhaled Nitric Oxide for Patients With MABSC | Phase2 | Mycobacterium Abscessus Infection | Completed | 2017-07-24 | 2019-04-11 | ClinicalTrials.gov |
| NCT03053388 | Evaluation of the Efficacy Safety and Tolerability of Nitric Oxide Given Interm… | Phase3 | Bronchiolitis | Completed | 2017-03-05 | 2018-04-28 | ClinicalTrials.gov |
| NCT01958944 | Evaluation of the Safety and Tolerability of Inhaled Nitric Oxide to Subjects W… | Phase1 | Cystic Fibrosis | Completed | 2013-12-01 | 2015-11-01 | ClinicalTrials.gov |
| NCT01768884 | Evaluation of the Safety and Tolerability of Nitric Oxide (NO) Via Inhalation t… | Phase1 | Bronchiolitis | Completed | 2013-01-01 | 2016-01-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE1 | Bronchiolitis | COMPLETED | NCT01768884 |
| Nitric Oxide | Other | Phase PHASE1 | Bronchiolitis | COMPLETED | NCT01768884 |
| Nitric oxide | Other | Phase PHASE1 | Cystic Fibrosis | COMPLETED | NCT01958944 |
| Nitric Oxide | Other | Phase PHASE2 | Mycobacterium Abscessus Infection | COMPLETED | NCT03208764 |
| Supportive treatment | Drug | Phase PHASE3 | Bronchiolitis | COMPLETED | NCT03053388 |
| Nitric Oxide | Other | Phase PHASE3 | Bronchiolitis | COMPLETED | NCT03053388 |
| Standard Supportive treatment | Drug | Phase PHASE2 | Bronchiolitis Acute | COMPLETED | NCT04060979 |
| Nitric Oxide | Other | Phase PHASE2 | Bronchiolitis Acute | COMPLETED | NCT04060979 |
| 80 ppm Nitric Oxide delivered through LungFit Delivery System | Other | Phase PHASE2 | COVID-19 | WITHDRAWN | NCT04456088 |
| 150 ppm Nitric Oxide delivered through LungFit Delivery System | Other | Phase PHASE2 | COVID-19 | WITHDRAWN | NCT04456088 |
| LungFit | Other | Approved | Non-Tuberculous Mycobacterial Pneumonia | COMPLETED | NCT04685720 |
| LungFit™ | Other | Approved | Viral Pneumonia | COMPLETED | NCT04606407 |
| Nitric Oxide delivered via LungFit™ system | Other | Approved | Corona Virus Infection | TERMINATED | NCT04397692 |
| Nitric Oxide selected dose | Other | Phase PHASE1 | Cancer | RECRUITING | NCT05351502 |
| Nitric Oxide 100,000 ppm | Other | Phase PHASE1 | Cancer | RECRUITING | NCT05351502 |
| Nitric Oxide 50,000 ppm | Other | Phase PHASE1 | Cancer | RECRUITING | NCT05351502 |
| Nitric Oxide 25,000 ppm | Other | Phase PHASE1 | Cancer | RECRUITING | NCT05351502 |
| Nitric Oxide selected dose | DRUG | Phase PHASE1 | Cancer | RECRUITING | NCT05351502 |
| Nitric Oxide 100,000 ppm | DRUG | Phase PHASE1 | Cancer | RECRUITING | NCT05351502 |
| Nitric Oxide 50,000 ppm | DRUG | Phase PHASE1 | Cancer | RECRUITING | NCT05351502 |
| Nitric Oxide 25,000 ppm | DRUG | Phase PHASE1 | Cancer | RECRUITING | NCT05351502 |
| LungFit | DEVICE | Approved | Non-Tuberculous Mycobacterial Pneumonia | COMPLETED | NCT04685720 |
| LungFit™ | DEVICE | Approved | Viral Pneumonia | COMPLETED | NCT04606407 |
| Nitric Oxide delivered via LungFit™ system | DEVICE | Approved | Corona Virus Infection | TERMINATED | NCT04397692 |
| Standard Supportive treatment | OTHER | Phase PHASE2 | Bronchiolitis Acute | COMPLETED | NCT04060979 |
| Supportive treatment | OTHER | Phase PHASE3 | Bronchiolitis | COMPLETED | NCT03053388 |
| Nitric oxide | DRUG | Phase PHASE1 | Cystic Fibrosis | COMPLETED | NCT01958944 |
| Placebo | DRUG | Phase PHASE1 | Bronchiolitis | COMPLETED | NCT01768884 |
| Nitric Oxide | DRUG | Phase PHASE2 | Bronchiolitis Acute | COMPLETED | NCT04060979 |